Program
IL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115
Also written as “FL115” and “FL115+PD-1”.
Its studies are mostly in Non-Muscle Invasive Bladder Neoplasms, led by Suzhou Forlong Biotechnology.
Drug pageIL-15(N72D)/IL-15Ralpha-sFc Fusion Protein Complex FL115: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Suzhou Forlong Biotechnology | 54 open or running | phase 2since Jul 21, 2025 | Nov 7, 2023 | Dec 5, 2026phase 2 · NCT07131202 |
Also a collaborator on its studies: Novotech (Australia) Pty.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 7, 2023First study: phase 1 study in Locally Advanced/Metastatic Solid TumorsFirst studyNCT06130722 · 18 enrolled · United States
- Jul 21, 20252 phase 2 studiesNCT07131202, NCT07122414
- Jul 21, 2025Phase 1 study in Locally Advanced/Metastatic Solid TumorsNCT07131189 · 30 enrolled · China
- Aug 20, 2026Phase 1 study in Advanced Solid TumoursNCT07785193 · 29 planned · Australia
Ahead
- Dec 5, 2026Primary completion: phase 2 study in Advanced Solid TumorsNCT07131202
- Sep 2027Primary completion: phase 1 study in Advanced Solid TumoursNCT07785193
- Oct 10, 2027Primary completion: phase 2 study in Non-Muscle Invasive Bladder NeoplasmsNCT07122414
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07785193Advanced Solid Tumours · Australia | 1 | Not yet recruiting | Sep 2027 | 29 |
| NCT07131202Advanced Solid Tumors · China | 2 | Recruiting | Dec 5, 2026 | 130 |
| NCT07131189Locally Advanced/Metastatic Solid Tumors · China | 1 | Active, not recruiting | Jun 1, 2026 | 30 |
| NCT07122414Non-Muscle Invasive Bladder Neoplasms · China | 2 | Recruiting | Oct 10, 2027 | 80 |
| NCT06130722Locally Advanced/Metastatic Solid Tumors · United States | 1 | Completed | Feb 15, 2025 | 18 |
How it is read
Names in the registry
- “FL115”, 4 entries
- “FL115+PD-1”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.